Drug metabolism in the lungs: opportunities for optimising inhaled medicines

References

• Courcot E, Leclerc J, Lafitte -J-J, et al. Xenobiotic metabolism and disposition in human lung cell models: comparison with in vivo expression profiles. Drug Metab Dispos. 2012;40(10):1953.
   PubMed Web of Science ®Google Scholar
• Oesch F, Fabian E, Landsiedel R. Xenobiotica-metabolizing enzymes in the lung of experimental animals, man and in human lung models. Arch Toxicol. 2019;93(12):3419–3489.
   PubMed Web of Science ®Google Scholar
• Taylor G. The absorption and metabolism of xenobiotics in the lung. J Advanced Drug Delivery Reviews. 1990;5(1–2):37–61.
   Google Scholar
• Olsson B, Bondesson E, Borgström L, et al. Pulmonary drug metabolism, clearance, and absorption. In: Smyth HDC, Hickey AJ, editors. Controlled pulmonary drug delivery. New York: Springer New York; 2011. p. 21–50.
   Google Scholar
• Devereux TR, Domin BA, Philpot RM. Xenobiotic metabolism by isolated pulmonary cells. Pharmacol Ther. 1989;41(1):243–256. 1989/01/01/
   PubMed Web of Science ®Google Scholar
• Foster KA, Oster CG, Mayer MM, et al. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res. 1998;243(2):359–366. 1998/09/15/
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Pelkonen O, Hakkola J, et al. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol. 2002;32(5):391–411. 2002/01/01
   PubMed Web of Science ®Google Scholar
• Jarvis IW, Enlo‐Scott Z, Nagy E, et al. Genotoxicity of fine and coarse fraction ambient particulate matter in immortalised normal (TT1) and cancer‐derived (A549) alveolar epithelial cells. Environmental Molecular Mutagenesis. 2018;59(4):290–301.
   PubMed Web of Science ®Google Scholar
• Piipari R, Savela K, Nurminen T, et al. Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon‐DNA adduct formation in bronchoalveolar macrophages of smokers and non‐smokers. Int J Cancer. 2000;86(5):610–616.
   PubMed Web of Science ®Google Scholar
• Thum T, Erpenbeck VJ, Moeller J, et al. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect. 2006;114(11):1655–1661.
   PubMed Web of Science ®Google Scholar
• Bernauer U, Heinrich-Hirsch B, Tönnies M, et al. Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol Lett. 2006;164(3):278–288. 2006/07/15/
   PubMed Web of Science ®Google Scholar
• Tournel G, Cauffiez C, Billaut-Laden I, et al. Molecular analysis of the CYP2F1 gene: identification of a frequent non-functional allelic variant. Mutat Res. 2007;617(1):79–89. 2007/04/01/
   PubMed Web of Science ®Google Scholar
• Anttila S, Hukkanen J, Hakkola J, et al. Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol. 1997 Mar;16(3):242–249. PubMed PMID: 9070608; eng.
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Väisänen T, Lassila A, et al. Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003;304(2):745.
   PubMed Web of Science ®Google Scholar
• Yildiz Y, Gareth W, Markus W, et al. Comparison of rat and human pulmonary metabolism using Precision-cut Lung Slices (PCLS). Drug Metab Lett. 2019;13(1):53–63.
   PubMedGoogle Scholar
• Rubin K, Ewing P, Bäckström E, et al. Pulmonary metabolism of substrates for key drug-metabolizing enzymes by human alveolar type II cells, human and rat lung microsomes, and the isolated perfused rat lung model. Pharmaceutics. 2020;12(2):117.
   Web of Science ®Google Scholar
• Somers GI, Lindsay N, Lowdon BM, et al. A Comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007;35(10):1797.
   PubMed Web of Science ®Google Scholar
• Van Dyck E, Nazarov PV, Muller A, et al. Bronchial airway gene expression in smokers with lung or head and neck cancer. Cancer Med. 2014;3(2):322–336. 2014/04/01
   PubMed Web of Science ®Google Scholar
• Zuo WL, Shenoy SA, Li S, et al. Ontogeny and biology of human small airway epithelial club cells. Am J Respir Crit Care Med. 2018 Dec 1;198(11):1375–1388. PubMed PMID: 29874100; PubMed Central PMCID: PMCPMC6290945. eng.
   PubMed Web of Science ®Google Scholar
• Howie AF, Forrester LM, Glancey MJ, et al. Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis. 1990 Mar;11(3):451–458. PubMed PMID: 2311189; eng.
   PubMed Web of Science ®Google Scholar
• Wang Y, Spitz MR, Schabath MB, et al. Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. Lung Cancer. 2003 Apr;40(1):25–32. PubMed PMID: 12660004; eng.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Cherry NM, Niven RM, et al. GSTM1, GSTT1 and GSTP1 polymorphisms and lung cancer risk. Cancer Lett. 2002;180(2):165–171.
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Franchi M, Bencini C, et al. Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica. 1988;18(7):849–856. 1988/01/01
   PubMed Web of Science ®Google Scholar
• Chen C-H. Genetic variations and polymorphisms of metabolic enzymes. In: Xenobiotic metabolic enzymes: bioactivation and antioxidant defenser. Springe, Cham; 2020. p. 155–168.
   Google Scholar
• Conway LP, Rendo V, Correia MS, et al. Unexpected acetylation of endogenous aliphatic amines by Arylamine N‐Acetyltransferase NAT2. In: Angewandte chemie international edition. 2020;59(34):14342–14346.
   Google Scholar
• Zhang JY, Fen Wang Y, Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab. 2006;7(8):939–948.
   PubMed Web of Science ®Google Scholar
• Jamaludin J, Marlin N, Wood H, et al. Evaluating the impact of genotype on the relationship between impaired lung growth and chronic exposure to traffic derived pollutants. Eur Respir J. 2013;42(Suppl 57):P3623.
   Google Scholar
• Tekpli X, Zienolddiny S, Skaug V, et al. DNA methylation of the CYP1A1 enhancer is associated with smoking‐induced genetic alterations in human lung. Int J Cancer. 2012;131(7):1509–1516.
   PubMed Web of Science ®Google Scholar
• Kuzuya Y, Adachi T, Hara H, et al. Induction of drug‐metabolizing enzymes and transporters in human bronchial epithelial cells by beclomethasone dipropionate. IUBMB Life. 2004;56(6):355–359.
   PubMed Web of Science ®Google Scholar
• Murai T, Reilly CA, Ward RM, et al. The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 Enzyme. Chem Res Toxicol. 2010;23(8):1356–1364. 2010/08/16
   PubMed Web of Science ®Google Scholar
• Stockmann C, Fassl B, Gaedigk R, et al. Fluticasone propionate pharmacogenetics: CYP3A4• 22 polymorphism and pediatric asthma control. J Pediatr. 2013;162(6):1222–1227.e2. 2013/06/01/
   PubMed Web of Science ®Google Scholar
• Roberts JK, Moore CD, Ward RM, et al. Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther. 2013;345(2):308–316. PubMed PMID: 23512537; eng.
   PubMed Web of Science ®Google Scholar
• Stockmann C, Reilly CA, Fassl B, et al. Effect of CYP3A5• 3 on asthma control among children treated with inhaled beclomethasone. J Allergy Clin Immunol. 2015;136(2):505–507.
   PubMed Web of Science ®Google Scholar
• Enlo-Scott Z, Swedrowska M, Forbes B. Epithelial permeability and drug absorption in the lungs. In: Inhaled Medicines. Elsevier; 2021. p. 267–299.
   Google Scholar
• Gundert-Remy U, Bernauer U, Blömeke B, et al. Extrahepatic metabolism at the body’s internal–external interfaces. Drug Metab Rev. 2014;46(3):291–324. 2014/08/01
   PubMed Web of Science ®Google Scholar
• Zeldin DC, Foley J, Ma J, et al. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol. 1996;50(5):1111–1117.
   PubMed Web of Science ®Google Scholar
• Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res. 1992;9(1):1–9. 1992/01/01
   PubMed Web of Science ®Google Scholar
• Brittebo EB. Metabolism-dependent activation and toxicity of chemicals in nasal glands. Mutat Res. 1997;380(1):61–75. 1997/10/31/
   PubMed Web of Science ®Google Scholar
• Dahl AR, Hadley WM. Nasal cavity enzymes involved in xenobiotic metabolism: effects on the toxicity of inhalants. Crit Rev Toxicol. 1991;21(5):345–372. 1991/01/01
   PubMed Web of Science ®Google Scholar
• Reed C. Drug metabolism in the nasal cavity: relevance to toxicology. Drug Metab Rev. 1993;25(1–2):173–205.
   PubMed Web of Science ®Google Scholar
• Oliveira P, Fortuna A, Alves G, et al. Drug-metabolizing enzymes and efflux transporters in nasal epithelium: influence on the bioavailability of intranasally administered drugs. Curr Drug Metab. 2016;17(7):628–647.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/Absorption/Elimination Interplay and Development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23. 2005/01/01
   PubMed Web of Science ®Google Scholar
• Nave R, Fisher R, McCracken N. In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices. Respir Res. 2007;8(1):65.
   PubMedGoogle Scholar
• Nonaka T, Nave R, McCracken N, et al. Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549). BMC Pharmacol. 2007;7(1):12. 2007/09/27
   PubMedGoogle Scholar
• Nave R, McCracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J Asthma Allergy. 2008;1:11–18. PubMed PMID: 21436981; eng.
   PubMedGoogle Scholar
• Pearce RE, Leeder JS, Kearns GL. BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION. Drug Metab Dispos. 2006;34(6):1035.
   PubMed Web of Science ®Google Scholar
• Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos. 1997;25(11):1311–1317.
   PubMed Web of Science ®Google Scholar
• Sahasranaman S, Issar M, Hochhaus G. METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES. Drug Metab Dispos. 2006;34(2):225.
   PubMed Web of Science ®Google Scholar
• Teng XW, Cutler DJ, Davies NM. Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos. 2003;24(8):321–333. 2003/11/01
   PubMed Web of Science ®Google Scholar
• Eaton EA, Walle UK, Wilson HM, et al. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol. 1996;41(3):201–206. 1996/03//. PubMed PMID: 8866919; eng.
   PubMed Web of Science ®Google Scholar
• Evans ME, Shenfield GM, Thomas N, et al. The pharmacokinetics of rimiterol in man. Xenobiotica. 1974;4(11):681–692.
   Web of Science ®Google Scholar
• Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356–363.
   PubMedGoogle Scholar
• Mukker JK, Singh RSP, Derendorf H. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids. J Pharm Sci. 2016;105(9):2509–2514. 2016/09/01/
   PubMed Web of Science ®Google Scholar
• Sato H, Nave R, Nonaka T, et al. In vitro metabolism of ciclesonide in human nasal epithelial cells. Biopharm Drug Dispos. 2007;28(1):43–50. 2007/01/01
   PubMed Web of Science ®Google Scholar
• Nave R, Meyer W, Fuhst R, et al. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2005;18(6):390–396. 2005/12/01/
   PubMed Web of Science ®Google Scholar
• Wieslander E, Delander E-L, Järkelid L, et al. Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro. Am J Respir Cell Mol Biol. 1998;19(3):477–484. PubMed PMID: 9730876
   PubMed Web of Science ®Google Scholar
• Borchard G, Cassará ML, Roemelé PE, et al. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu‐3). J Pharm Sci. 2002;91(6):1561–1567.
   PubMed Web of Science ®Google Scholar
• Hemmerling M, Nilsson S, Edman K, et al. Selective nonsteroidal glucocorticoid receptor modulators for the inhaled treatment of pulmonary diseases. J Med Chem. 2017;60(20):8591–8605. 2017/10/26
   PubMed Web of Science ®Google Scholar
• Nassr N, Huennemeyer A, Herzog R, et al. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N‐oxide in healthy subjects. Br J Clin Pharmacol. 2009;68(4):580–587.
   PubMed Web of Science ®Google Scholar
• Huennemeyer A, Hauns B, David M, et al. Pharmacokinetics and safety of Roflumilast, a once-daily, oral, selective PDE4 inhibitor, and its active metabolite Roflumilast N-oxide in healthy subjects. J Allergy Clin Immunol. 2004;113(2, Supplement):S222. 2004/02/01/
   Google Scholar
• Lahu G, Nassr N, Hünnemeyer A. Pharmacokinetic evaluation of roflumilast. Expert Opin Drug Metab Toxicol. 2011;7(12):1577–1591. 2011/12/01
   PubMed Web of Science ®Google Scholar
• Murad HA, Habib HS, Rafeeq MM, et al. Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice. Experimental Biology and Medicine. 2017;242(5):516–526.
   Web of Science ®Google Scholar
• Éy S, Amaro MI, De Almeida GS, et al. Development of a new formulation of roflumilast for pulmonary drug delivery to treat inflammatory lung conditions. Int J Pharm. 2018;550(1):89–99. 2018/10/25/
   PubMedGoogle Scholar
• Sun D. Remdesivir for Treatment of COVID-19: combination of pulmonary and iv administration may offer aditional benefit. Aaps J. 2020;22(4):1–6.
   Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):396.
   Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385.
   PubMed Web of Science ®Google Scholar
• Yan V, Muller F. Advantages of the parent nucleoside GS-441524 over remdesivir for Covid-19 treatment. ACS Med Chem Lett. 2020;11(7):1361–1366.
   PubMed Web of Science ®Google Scholar
• Yang K. What do we know about remdesivir drug interactions? Clin Transl Sci. 2020;13(5):842–844.
   PubMed Web of Science ®Google Scholar
• Baginski L, Tachon G, Falson F, et al. Reverse transcription polymerase chain reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011;24(2):89–101.
   PubMed Web of Science ®Google Scholar
• Forbes B, Wilson C, Gumbleton M. Temporal dependence of ectopeptidase expression in alveolar epithelial cell culture: implications for study of peptide absorption. Int J Pharm. 1999;180(2):225–234.
   PubMedGoogle Scholar
• Morita T, Yamamoto A, Takakura Y, et al. Improvement of the pulmonary absorption of (Asu 1, 7)-eel calcitonin by various protease inhibitors in rats. Pharm Res. 1994;11(6):909–913.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Kondo S, Juni K. Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers. Pharm Res. 1994;11(9):1239–1243.
   PubMed Web of Science ®Google Scholar
• Hussain A, Arnold JJ, Khan MA, et al. Absorption enhancers in pulmonary protein delivery. J Control Release. 2004;94(1):15–24.
   PubMed Web of Science ®Google Scholar
• Woods A, Andrian T, Sharp G, et al. Development of new in vitro models of lung protease activity for investigating stability of inhaled biological therapies and drug delivery systems. Eur J Pharm Biopharm. 2020;146:64–72. 2020/01/01/
   PubMed Web of Science ®Google Scholar
• Frederiksen B, Pressler T, Hansen A, et al. Effect of aerosolized rhDNase (Pulmozyme®) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatrica. 2006;95(9):1070–1074.
   PubMed Web of Science ®Google Scholar
• Guichard MJ, Leal T, Vanbever R. PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals. Curr Opin Colloid Interface Sci. 2017;31:43–50. 2017/09/01/
   Web of Science ®Google Scholar
• King PT, Sharma R, O’Sullivan KM, et al. Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung. Sci Rep. 2017;7(1):12128. 2017/09/21
   PubMedGoogle Scholar
• Griese M, Scheuch G. Delivery of Alpha-1 antitrypsin to airways. Ann Am Thorac Soc. 2016;13(Supplement 4):S346–S351.
   PubMedGoogle Scholar
• Brantly M, Stocks J, Rouhani F, et al. Inhaled alpha-1-antitrypsin restores lower respiratory tract protease-anti-protease homeostasis and reduces inflammation in alpha-1 antitrypsin deficient individuals: a phase 2 clinical study using inhaled kamada-api. C74. ADVANCES IN TRANSLATIONAL COPD: American Thoracic Society. 2017;A7677–A7677.
   Google Scholar
• Barrecheguren M, Miravitlles M. Treatment with inhaled α1-antitrypsin: a square peg in a round hole? Eur Respir J. 2019;54(5):1901894.
   PubMed Web of Science ®Google Scholar
• Stolk J, Tov N, Chapman KR, et al. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019;54(5):5.
   Web of Science ®Google Scholar
• Morales JO, Fathe KR, Brunaugh A, et al. Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes. Aaps J. 2017;19(3):652–668. 2017/05/01
   PubMed Web of Science ®Google Scholar
• Martinelli F, Balducci AG, Kumar A, et al. Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery. Int J Pharm. 2017;517(1):286–295. 2017/01/30/
   PubMedGoogle Scholar
• Mantaj J, Abu-Shams T, Enlo-Scott Z, et al. Role of the basement membrane as an intestinal barrier to absorption of macromolecules and nanoparticles. Mol Pharm. 2018;15(12):5802–5808. 2018/12/03
   PubMedGoogle Scholar
• Kumar A, Terakosolphan W, Hassoun M, et al. A biocompatible synthetic lung fluid based on human respiratory tract lining fluid composition. Pharm Res. 2017;34(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Surendrakumar K, Martyn GP, Hodgers ECM, et al. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release. 2003;91(3):385–394. 2003/09/04/
   PubMed Web of Science ®Google Scholar
• Guerreiro F, Pontes JF, Am RDC, et al. Spray-drying of konjac glucomannan to produce microparticles for an application as antitubercular drug carriers. Powder Technol. 2019;342:246–252. 2019/01/15/
   Web of Science ®Google Scholar
• Islam N, Dmour I, Taha MO. Degradability of chitosan micro/nanoparticles for pulmonary drug delivery. Heliyon. 2019;5(5):e01684. 2019/05/01/
   PubMed Web of Science ®Google Scholar
• Juhász C, Muzik O, Lu X, et al. Quantification of tryptophan transport and metabolism in lung tumors using PET. J Nucl Med. 2009 Mar;50(3):356–363. PubMed PMID: 19223408; PubMed Central PMCID: PMCPMC2784997. eng.
   PubMed Web of Science ®Google Scholar
• Faubert B, Li KY, Cai L, et al. Lactate metabolism in human lung tumors. Cell. 2017;171(2):358–371.e9. 2017/10/05/
   PubMed Web of Science ®Google Scholar
• Mittal S, Chowhan RK, Singh LR. Macromolecular crowding: macromolecules friend or foe. Biochim Biophys Acta Gen Subj. 2015;1850(9):1822–1831. 2015/09/01/
   Web of Science ®Google Scholar
• Silverstein TP, Slade K. Effects of macromolecular crowding on biochemical systems. J Chem Educ. 2019;96(11):2476–2487. 2019/11/12
   Web of Science ®Google Scholar
• Kim JS, Yethiraj A. Effect of macromolecular crowding on reaction rates: a computational and theoretical study. Biophys J. 2009;96(4):1333–1340. 2009/02/18/
   PubMed Web of Science ®Google Scholar
• Ward JK, Dow J, Dallow N, et al. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man — no evidence of enantioselective lung metabolism. Br J Clin Pharmacol. 2000;49(1):15–22. 2000/01/01
   PubMed Web of Science ®Google Scholar
• Aridgides DS, Mellinger DL, Armstrong DA, et al. Functional and metabolic impairment in cigarette smoke-exposed macrophages is tied to oxidative stress. Sci Rep. 2019;9(1):1–11.
   PubMedGoogle Scholar
• Hussain T, Al-Attas OS, Al-Daghri NM, et al. Induction of CYP1A1, CYP1A2, CYP1B1, increased oxidative stress and inflammation in the lung and liver tissues of rats exposed to incense smoke. Molecular and Cellular Biochemistry. 2014;391(1–2):127–136.
   PubMed Web of Science ®Google Scholar
• Ehrmann S, Schmid O, Darquenne C, et al. Innovative preclinical models for pulmonary drug delivery research. Expert Opin Drug Deliv. 2020;17(4):463–478. 2020/04/02
   PubMed Web of Science ®Google Scholar
• Castell JV, Teresa Donato M, Gómez-Lechón MJ. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. Exp Toxicol Pathol. 2005;57:189–204. 2005/07/22/
   PubMed Web of Science ®Google Scholar
• Cohen GM. Pulmonary metabolism of foreign compounds: its role in metabolic activation. Environ Health Perspect. 1990;85:31–41.
   PubMed Web of Science ®Google Scholar
• Okona-Mensah KB, Battershill J, Boobis A, et al. An approach to investigating the importance of high potency polycyclic aromatic hydrocarbons (PAHs) in the induction of lung cancer by air pollution. Food Chem Toxicol. 2005;43(7):1103–1116. 2005/07/01/
   PubMed Web of Science ®Google Scholar
• Dahl AR, Gerde P. Uptake and metabolism of toxicants in the respiratory tract. Environ Health Perspect. 1994;102(suppl 11):67–70.
   PubMedGoogle Scholar
• Chapter HE. 38 - metabolism of pesticides. In: Krieger R, editor. Hayes’ Handbook of Pesticide Toxicology (Third Edition). New York: Academic Press; 2010. p. 893–921.
   Google Scholar
• Gram TE. Chemically reactive intermediates and pulmonary xenobiotic toxicity. Pharmacol Rev. 1997;49(4):297.
   PubMed Web of Science ®Google Scholar
• Li L, Carratt S, Hartog M, et al. Human CYP2A13 and CYP2F1 mediate naphthalene toxicity in the lung and nasal mucosa of CYP2A13/2F1-humanized mice. Environ Health Perspect. 2017;125(6):067004.
   PubMed Web of Science ®Google Scholar
• Parkinson OT, Teitelbaum AM, Whittington D, et al. Species differences in microsomal oxidation and glucuronidation of 4-ipomeanol: relationship to target organ toxicity. Drug Metab Dispos. 2016;44(10):1598–1602. PubMed PMID: 27468999; eng.
   PubMed Web of Science ®Google Scholar
• Wiek C, Schmidt EM, Roellecke K, et al. Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol. Biochem J. 2015;465(1):103–114. PubMed PMID: 25247810; eng.
   PubMed Web of Science ®Google Scholar
• Foth H. Role of the lung in accumulation and metabolism of xenobiotic compounds — implications for chemically induced toxicity. Crit Rev Toxicol. 1995;25(2):165–205. 1995/01/01
   PubMed Web of Science ®Google Scholar
• Owen K. Regulatory toxicology considerations for the development of inhaled pharmaceuticals. Drug Chem Toxicol. 2013;36(1):109–118. 2013/01/01
   PubMed Web of Science ®Google Scholar
• Seo J, Huh D. Chapter 7 - Microphysiological models of human organs: a case study on microengineered lung-on-a-chip systems. In: Borenstein JT, Tandon V, Tao SL, editors. Microfluidic cell culture systems. Second. Elsevier.187–208. 2019.
   Google Scholar
• Yamamoto E, Taquahashi Y, Kuwagata M, et al. Visualizing the spatial localization of ciclesonide and its metabolites in rat lungs after inhalation of 1-μm aerosol of ciclesonide by desorption electrospray ionization-time of flight mass spectrometry imaging. Int J Pharm. 2021;595:120241. 2021/02/15/
   PubMedGoogle Scholar
• Dexter A, Steven RT, Patel A, et al. Imaging drugs, metabolites and biomarkers in rodent lung: a DESI MS strategy for the evaluation of drug-induced lipidosis. Anal Bioanal Chem. 2019;411(30):8023–8032. 2019/12/01
   PubMed Web of Science ®Google Scholar